Imagen Therapeutics presents
A new strategy for personalising chemotherapy
Imagen Therapeutics will present two complimentary 1 hour educational seminars presenting 'A new strategy for personalising chemotherapy’. Courtesy of LOC, the seminars will be hosted at The Board Room, First Floor, 95 Harley Street London on the below dates. Light refreshments will be served.
From 6.00 pm (evening) Wednesday 2nd November 2016
From 7.30 am (morning) Wednesday 9th November 2016
Rod Benson PhD will discuss:
- Why the need for personalisation is even greater given such a wide range of targeted therapies.
- Historical approaches to personalising chemotherapy (genetic profiling, protein bio-marker analysis, PDX models, chemosensitivity assays).
- Possible approaches to address the need to personalise chemotherapy (genetic profiling, protein bio-marker analysis, PDX models, early chemosensitivity assay)
- Why this solution is an improvement on all previous methods.
- How Imagen can work with consultant oncologists.
Who should attend?
Oncology leaders and specialists who are devoted to individual patient care.
When & Where
Imagen Therapeutics Ltd
Imagen Therapeutics’ chemosensitivity test measures the effectiveness of a wide range of licensed cytotoxic drugs and targeted therapies in killing cancer cells derived directly from an individual patient. The in vitro response data is calibrated against a training set comprising of patients with the same cancer as the one under investigation. This precise and personalised approach helps the treating clinician to make an informed decision on which drug theraphy is most likely to be effective for a particular cancer patient. The test is based on automated fluorescence microscopy (High Content Analysis) so cell death is determined directly and not via a surrogate measure such as the reduction of tetrazolium dye (MTT assay).